Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Excel PharmaStudies Chairman Mark Engel On China’s Rapidly Expanding Clinical Trials: An Interview With PharmAsia News (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Excel PharmaStudies, established in 2000, is one of the leading clinical research organizations in China. Excel PharmaStudies Chairman Mark Engel recently talked with PharmAsia News' Beijing bureau about the high-speed development of China's pharmaceutical market and the role of clinical trials in China. Engel also outlined challenges, solutions and opportunities regarding clinical trials in China.

You may also be interested in...



PPD Continues High-speed Expansion In Asia With Second Acquisition Of A China-based CRO This Quarter

BEIJING - As part of a rapid-fire expansion across Asia, the U.S.-headquartered PPD has outlined plans to purchase and merge with the Beijing-based contract research organization BioDuro

PPD Continues High-speed Expansion In Asia With Second Acquisition Of A China-based CRO This Quarter

BEIJING - As part of a rapid-fire expansion across Asia, the U.S.-headquartered PPD has outlined plans to purchase and merge with the Beijing-based contract research organization BioDuro

PPD Continues High-speed Expansion In Asia

U.S.-based CRO makes its second acquisition this quarter of a Chinese CRO.

Related Content

UsernamePublicRestriction

Register

OM011382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel